The Struggle Is Real For Alphabet… And A New Player In The Weight Loss Drug Battle 2/26/24

26 Feb 2024 · 43 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" Episode on Alphabet and Weight Loss Drugs (2/26/24)

Episode Overview In this episode of "Fast Money," hosted by Melissa Lee, the focus is on Alphabet's ongoing challenges in the AI race and the emerging competition in the weight loss drug market. The panel of traders discusses Alphabet's stock performance, leadership concerns, and AI product issues, alongside developments in the pharmaceutical industry regarding obesity treatments.

Key Topics Discussed

  1. Alphabet's Struggles
  2. Stock Performance:
  3. Alphabet's shares dropped over 4%, marking a 10% decline from earlier this year.
  4. Compared to its peers, Alphabet has significantly underperformed, especially against companies like Meta and Microsoft.
  • AI Issues:
  • Alphabet announced a relaunch of its Gemini AI, which had been pulled back due to quality concerns.
  • The panel discussed the perception that Alphabet has lagged behind competitors in the AI space since the rise of ChatGPT.
  • Leadership and Messaging:
  • Concerns were raised about Alphabet's leadership and its ability to communicate effectively about its AI strategy.
  • The panel suggested that a lack of confidence among investors is impacting stock performance.
  • Valuation Concerns:
  • The stock's valuation relative to its growth potential raises questions about its future performance and whether it can reclaim its status in the tech sector.
  1. Pharmaceutical Developments in Weight Loss
  2. Emerging Competitors:
  3. Zeeland Pharma's new obesity drug showed promising results, leading to a surge in its stock price.
  4. The panel explored how this new player could impact the market, already dominated by giants like Novo Nordisk and Eli Lilly.
  • Market Dynamics:
  • The discussion highlighted the complexities of the obesity drug market, including different patient populations and efficacy rates.
  • Concerns were voiced regarding the sustainability of existing players amid increasing competition.
  1. Broader Market Commentary
  2. International Investments:
  3. Discussion touched on Warren Buffett's increased investment in Japan, emphasizing the attractiveness of Japanese equities.
  • Bitcoin and Crypto Market:
  • Bitcoin's resurgence above $54,000 was noted, with implications for crypto investment opportunities.
  • Earnings Reports:
  • The panel analyzed earnings reports from companies like Zoom and Workday, emphasizing the volatility in tech stocks and the broader economic implications.

Key Takeaways

  • Alphabet's Future:
  • The panel is divided on Alphabet's potential recovery. Concerns about leadership and product quality persist, but some see an opportunity for investors to buy in at lower prices.
  • Weight Loss Drug Market:
  • The advent of new competitors like Zeeland Pharma may challenge established players, signaling a potential shift in the market landscape.
  • Investment Strategies:
  • Investors are encouraged to seek opportunities in both established companies and emerging players, especially in sectors like pharmaceuticals and technology.

Conclusion The episode encapsulates the ongoing challenges faced by Alphabet in the rapidly evolving AI landscape and highlights the competitive dynamics in the weight loss drug market. The discussions provide valuable insights into investment strategies amid these developments, reflecting the panel's diverse perspectives on market opportunities.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:03Live from the Nasdaq market site in the heart of New York City's Times Square. This is fast multiple stocks seem to get out of its own way. Plus, opportunities abroad. Buffett's Berkshire is betting big on Japan, and the ambassador is here with us with his own picks in the region where he's got a yen for investing. Oh, my. What a new entry in the weight loss drug battle could mean for the giants in the field. Bitcoin bounces above$54 ,000 and takes the rest of the crypto space with it. And zooming in on Zoom earnings, where shares of the pandemic darling are going next. I'm Melissa Lee coming to you live from Studio B at the NASDAQ on The Destinite.

0:49Tim Seymour, Steve Brasso, Dan Nathan, and Guy Adami. We start off with yet another stumble for Google in the AI race. The company is saying today it will relaunch its Gemini AI picture generator in a few weeks. The software, which just debuted this month, was pulled on Thursday after users reported historical errors and dubious responses in its output. Shares of parent company Alphabet dropping more than 4 % today. Notables stand out today. They're now down more than 10 % off the highs of the year, and today's move puts the stock in the red for the year. Alphabet has been far underperforming its AI rivals, meta jumping 36 percent this year, while Microsoft is up 8 percent.

1:26So why does Google seem to be struggling so much in this AI space, Guy? I think it's a number of reasons. First of all, I think they have a messaging problem without question. At that emergency meeting, remember a few months ago to talk about different things? I think they're doing a really difficult, they're having a difficult job explaining how they've been in AI probably longer than any other company out there, maybe not name Microsoft or Apple. But I also think to a large extent, it has to do with all these high-flying tech names that have taken their thunder away. I mean, why being a Google that's going to move maybe a couple percent over the course of a couple weeks as opposed to an NVIDIA or a Micron or a Broadcom that trades up 2%, 3 % seemingly hour to hour on a daily basis.

2:02So I think that's part of the problem as well. Technically, it's the third problem. If we could put up a chart, I mean, the level we just traded up to were the same highs we made back in December of 2021. So now the technicians will look at this and say there's a major double top here as well. So there are a litany of things to be concerned about. Of course, valuation has always been compelling. It seems to be going down on the same things all the time. I mean, it's always a concern about where it is in the AI race that it's falling behind, that its product isn't as good as Microsoft or other competitors, that maybe there are upstarts out there that will eat its lunch anyway, but down on the same things.

2:36Yeah. So going back to the BARD launch in January of 2023, Right. This was after ChatGPT came out three and a half, I guess, and really took the whole tech community by storm. It really surprised a lot of folks here. And, you know, it's just really important to note that this stock was trading at$90 back then. OK, so it closed today at$137.50. So, you know, Tim will mention it has kept pace with a lot of the stocks once it kind of got back on its horse. I think what Guy's point is, it's just the narrative. This is a company that going back seven years said it is an AI first company. They spend a lot of money on machine learning, you know, tens of billions of dollars probably over the last decade or so.

3:13So the fact that they could actually have an upstart like OpenAI really kind of eat their lunch in a way, you know, that is now going back 14, 15 months or so. At least that's been, you know, publicized. So here you are now. And then it comes down to something that has been a really difficult topic within tech over the last six or seven years about who are programming these systems, who have access to these systems. This is the reason why this stock is down a lot today in particular. The whole tech world is in a bit of a backlash here. So I think investors are shooting first, asking questions later because they don't have a whole heck of a lot of confidence that BARD or Gemini Advance is going to be re-released as something that's going to be up to snuff with the ones that are doing well right now.

3:51But if the concern is who has control over the algorithms and what these models spit out in terms of being able to, you know, massage history or whatever you want to call it, misinformation, why aren't all the tech giants down then? Why isn't the indictment made against all of the companies that have the same problem theoretically? Because they've done enough. There's been no wow factor here. And I think about it more from playing defense. They can't play defense in an environment where we're on the cusp of people approaching search in an entirely new way. Dan brought this up. where the place is.

4:21I'm not going to necessarily be doing anything different with my phone than going to Google. But if I'm sitting at my desktop, Microsoft might have a shot where they never had a shot with Bing. So I think that's part of what's going on here. I mean, you can look at other of the mega cap names and you can look at Apple and say what's going on there. Apple's underperformed the S &P by 16 % since early December. It's down 5 % or 6 % year to date. So it's really underperforming. And we're not really attacking Apple under this construct. So I do think all of the headlines around AI are that it's a challenge to the legacy business, not playing offense like Meta and obviously like NVIDIA.

4:57But of other names that it's not really the core of what they do is to make AI chips. It's really Meta and somewhat Amazon and everybody else. They own search. So let's start off with where their strength is. Right now. They own search right now. But when you look at AI, this is their own mess up. They did this. They have an agenda. And the problem is they they did this, not the other companies where you said, how come everything is not down sort of in sympathy? This is their own mess. They have to clean it up. So can they clean it up? Will they ever be trusted to? And when you look at where A.I.

5:30came about, they were lagging. Dan touched on it. They were lagging from day one. And when you look at the chart, I knew I was guy was in my head. I was in guy's head. When you look at that chart, that double top, you know, well, suffers from that Amazon almost. So for now, Google, I sold my Google today. I don't think they're capable of fixing it on their own. And I think they're idiosyncratic with the rest of the tech space. Are we being too hard on Alphabet? I think so. Because this is not the first time we've asked what is wrong with Alphabet. I feel like I've fought their corner. You know, I am definitely.

6:05Who's some of the more famous boxing managers that you want in your corner? Corner people, actually. The fight doctor, Dr. Ferdi Pacheco. That would be your type of guy. Call me the fight, doctor. But I think this is a case where Google's performance is something that over the last year certainly has been absolutely fine. Over the last two months, it's been awful. And it's been awful relative to a couple names. But isn't it not their fault last spring when we were talking about the same thing? I don't know, because I'm not sure we really know how to value anybody's AI business. I agree with the line that Dan said, which is that they've done a terrible job communicating their strategy to markets.

6:43But I'm not sure we know what anybody's real market is, again, outside of it gets back to that question we asked that one day where we asked, is the pie any bigger than it was entirely in the world in terms of either enterprise or consumer dollars or whatever we're calling the marginal erosion? In Google's case, right now, the market is assuming that there is not just marginal, that there's very real erosion in their core search business. And I'm not sure that that is right. Look, I think there's a lot of people out there looking for opportunities to buy weakness, especially significant weakness in some of these names.

7:12Look at Meta. Suddenly, you know, everybody hated Meta at 10 times, and now they love it at 24 times. And I do think you could see something like that with Google. I agree with you that there are certain assumptions being made to the attack on its core search business. But isn't it just sort of just the fact that it is unknown, that the impact is unknown? And let's say Google is standing in place with its AI offering, and it's not that great, but that it is not enough, what they have is not enough to be a moat to defend their current search business. So they even lose a percentage of that. Sure.

7:40And every percentage is something to the stock. Cus the motto. Cus the motto. That's Tyson's. I'm sorry. That's Tyson's guy. No, you bring up a great point. And then my pushback would be that's why it's valued with a market multiple as opposed to some of the multiples a lot of these other companies. It's already in. Well, we'll see about that. But the flip side, another side of this coin, multifaceted is, if you think somehow magically this whole high valuation, high growth tech stock trade is going to not implode, but start to go the other way, you're going to find safety in names like Google 100 percent.

8:14I think the dollars will find their way there. Yeah, I'll just mention this, though. Like seven years ago, when, you know, Google Alphabet first called it, I think there was still Google back then, said they're an AI first company. They had nearly 79 percent gross margins. They're expected to have 61 percent gross margins. So if you talk about a monopoly that they have in and around search, which is one of the best. You hear tech luminaries say it all the time. It was one of the best business models ever built. And then you have that sort of monopoly and you're starting to lose it and it's becoming less profitable.

8:41And all of a sudden now there are upstarts out there. OK, like a perplexity or something like that. People are talking about companies like that the way that we're talking about Google challenging incumbents 20 years ago. OK, so think about that. And so that's how technology works. So to me, I think that it probably makes sense that you have this underperformance. I think it is a show me story. I think there will be some layoffs, some high profile stuff. I think there is pressure. I saw Deirdre Bosa this morning on Tech Check talking about the Sundar under pressure, that sort of thing. That's how you have to affect big change.

9:14That's how you have to get better marketing. They will come out with a better product and it will be retooled, that sort of thing. So you almost want this thing to get hit really hard, to trade way below a market multiple. Sounds like another guy standing in his corner. Maybe, and again, Mickey. Mickey and Rocky. Or Kevin Rooney, right? Another Tyson. Mickey, Burgess Meredith. One of his best roles, really. Mickey and Bill. No doubt about it. Well, he was also like in the back. He was riveting as a conversation. Well, but we didn't do any. Usually we start with housekeeping. Welcome back, Steve Grosso on vacation.

9:42Tim Seymour on vacation. Welcome back. Melissa Lee on vacation. Some of us just worked right through. Yesterday was Finnerman's birthday. I know. Yesterday, I'm pointing over my shoulder. Sorry. Back to you. This is, just to put one last ball on it, this is Google's problem. We're all making this way too complicated. This search issue that they had with the not factually correct is their own issue. This was totally avoidable. This is something that was their agenda. They shot it out, and they're paying. Sounds like an opportunity. For whom? Well, for Google investors right now to step in. Well, it sounds like a very fixable problem.

10:15Yeah. If they want to fix it. Why wouldn't they want to fix it? It's factually incorrect. They did it. They did it on their own. So they have an agenda. Let's let's get to our guests here. Even with Google stock taking that four point four percent hit after today's announcement, our next guest still has a one hundred seventy five dollar price target on the stock. Oppenheimer's Jason Helstein joins us now to talk about why he sees so much room to the upside. Jason, great to have you with us. Why do you think Google's been underperforming over the past couple of months? I understand you can pick any sort of different time frame, but within the past couple of months, what do you think its problems have been?

10:47What can Sundar Pichai do? Really, it's really a lack of confidence and leadership. Probably the best example would be, this is like, you know, asking somebody to get in a Waymo that will only go 20 miles an hour. No one's going to want to do that, right? So right now, the company is putting too many guardrails on their AI because they're too concerned about, you know, the criticisms. And they just have to kind of lean in and stop being so defensive. So you're saying they actually have the technology, but they're sort of throttling it to make sure that there are controls on it because they're doing that and they're still spitting out incorrect or dubious results.

11:29So what kind of guardrails are they? I mean, none of us know, you know, how well the technology really works under the hood. Right. But we do know this is a company who knows how to index the entire Internet better than anyone else. If you look at the data, you know, if you look at the usage of Google from November to January is up 3 % according to SimilarWeb. Bing is up 7%, but as a percent of users, Google is still like 98%. If you look at percent of searches, they're at 91%. And going back a year and a half, they were something at like 92%, right? So the point is that this company knows how to index and find information better than any other company in the world.

12:14And the question is, is why won't they allow that information to come through? And again, it just seems like there's just too many training wheels that have been put on on their generative AI product. And it's actually hurting the output to the point where just investors have lost confidence right now. But, Jason, it's Tim. Thanks for joining us. Is search behavior about to change, I guess, is my question to you, in a way that Google's former dominance, and you talked about those numbers every time people count them out. And I know you're going Lou Duva on him, fighting their corner as well. Footnote, Sandy Cannell.

12:52Your thoughts here? I mean, because if search is about to change as we know it, it really opens up the playing field. Again, I think what people were really excited about with ChatGPT was just how it had almost like a human-like interaction, right? And it captivated consumers. I could basically have a conversation with a computer way more efficient than Alexa or Siri, okay? But when people actually started getting into fact-checking, there were a lot of issues, right? And so what people have been using generative AI for is the automation of tasks, right? Like put something in, summarize it, right?

13:28Which again, the thought is Gemini actually does that pretty well. But the criticism is really when you're using it more like a search. You're asking it a question, right? Like who is better for the world, this person or that person, right? Or create an image of XYZ and it won't do it or the image just kind of doesn't make sense. And so, you know, ultimately, you know, Google is giving you, you know, typically we use it in business, right? Like four or five results and you use your intelligence. So this is the one I want to look at. Right. You know, do we get to the point where it just gives me one?

14:08And again, it just seems like we're still kind of very far away from that. But Google should let Gen.ai do what Gen.ai does. Right. Which is you're asking it to automate things and et cetera. So, again, like I think we all need to see kind of what this looks like without the training wheels. And that's really like a management decision and then being willing to basically accept the criticism. Right. Like it will be an imperfect product, but like let it function. Have you talked to management about letting the training wheels off or about the loss of investor confidence? No, they don't take much criticism from sell side analysts on that.

14:47I thought maybe maybe on the conference call. Jason, great to have you with us. Jason Helfstein. All right. So, I don't know. Let the training. Is it as simple as that? Let the training go. I think these guys all have it. I mean, like, listen, some things need to be tweaked. Some people need to go. They need to actually have a remessaging. They need to relaunch the product. I mean, this is a product. We did our little demo a couple weeks ago. They don't even have an app yet, right? Obviously, they own Android. And so that was like a thing that they wanted to focus on first. And that's got great market share globally and get the free product out there.

15:19But like this is not great. Right. But this is one of those things I think we'll look back and be like, it was probably just a blip. Unless, to Tim's point, does Microsoft with Bing and, you know, chat GBT4, do they start to make some inroads? Do some of these upstarts start to do that? I think it's also important to remember the last two times that this company has reported earnings and given guidance, the stock has gapped down seven and a half percent and nine and a half percent respectively from 52 week highs. So investors have been willing to take it back up after these sorts of reports. But there are some problems in their business that are not at least living up to investor expectations right now.

15:54I mean, efficiencies is one problem. If they had a year of efficiency like Meta had, I think rebranding that would be amazing for the stock. It would be a lift of some sort. This is something where I bought it thinking they were going to catch up in AI. I thought this was going to be their year for AI. When you look at an NVIDIA, there's nothing that you have to – no qualm over. You have your chip. You know what you're getting. You know that they have an 86 percent market share there. Google has an over 90 percent. We heard Jason talk about the exact number over 90 percent market share in search.

16:26It was theirs to keep in A.I. and they don't have it. It's interesting because when Ruth Porat took the helmet at Google Alphabet, whatever we're calling it, it was about to be the year of efficiency. It was going to be transparency into all the different structures. Some of that really worked out of the gates and some of that has stalled. All right. We've got a news alert here on Chevron's acquisition of Hess. Pippa Stevens got the details. Pippa. Melissa, well, Chevron's saying just now that it may not complete the acquisition of Hess within the time frame the company anticipates or even at all.

16:53And that is thanks to ExxonMobil and China National Offshore Oil Corporation saying that they have a right to a first refusal provision in that joint operating agreement for the offshore Guyana asset. That, of course, is why Exxon wanted to acquire Hess because of Hess's 30 percent stake in that Guyana offshore project. Now, Exxon said that those conversations will continue and that they owe it to their investors and partners to consider their preemption rights in place under their joint operating agreement. Now, to be clear, it is not sure at this time if Exxon will actually make a counterbid.

17:30But for right now, they are saying that they have the right to do so, with Chevron saying that it could then delay or possibly cancel their deal to buy Hess. Melissa? All right, Pippa, thanks. Pippa Stevens. That's quite a turn, Tim. It's quite a turn. It's interesting because Chevron did not rally on this deal. This is the most exciting oil exploration site in the world and a place that people are fighting all over, yet it wasn't rewarded. If you own Chevron here, I don't think the lack of this deal follow through is alarming. And in fact, their ability to pay down debt over the last four years and be able to break even on their divot around$45 oil is reason alone to buy Chevron.

18:11But I think this is a world class company. That's the takeaway. The stock sold off when they announced it, and it's selling off when it looks like it's not going to happen. So they lose both ways, which is typically what happens to me. But this is a stock, I mean, you talk about valuation 11 times next year's numbers, balance sheets such that they were able to announce a$75 billion stock buyback a couple falls ago that seemingly marked the top of the stock. So I think, again, these big cap integrated names, you're buying weakness. All right, coming up, a Berkshire backing. Warren Buffett's company upping its stake in the land of the rising sun.

18:41But where exactly should you be in the trade? Our emerging market specialist, Ambassador Tim Seaman, lays out his fix in the region next. Plus, Bitcoin's fabulous February. The crypto surging nearly 30 percent so far and on pace for its best month in over a year. The stocks and proxies benefiting from that bounce when Fast Money returns.

19:02This is Fast Money with Melissa Lee right here on CNBC.

19:14Welcome back to Fast Money. Berkshire Hathaway shares hitting a new all-time high before pulling back today. Warren Buffett's company reported record profit in cash levels over the weekend. It's also upping its bet on Japan, saying it's increased its holdings in five very large, highly diversified Japanese companies. The average stake in those names now standing at nearly 9 percent. So if Warren Buffett is all in on Japan, should you be? We asked our emerging market specialist in the House, the ambassador, Tim Seymour, for his top pick. So, Tim, what are your top picks? Yeah, I mean, look, I feel like I've been bullish on Japan for a long time.

19:48It's one of the heaviest weight in the international ETF I advise on. And it's a case where Japan, to me, it gets better and better because the macro around it is we know deflation is over. We know, if anything, the Bank of Japan is actually no longer going to be targeting the yield curve. But down to companies themselves, the payout levels are growing. There's pressure on them from the Tokyo Stock Exchange to actually increase those payout levels. So the three names that I think are the most interesting, and again, these are the three of the heavyweights in Idevo. Mitsubishi, MUFG is the ticker.

20:16It's clearly the JP Morgan of Japan. You're getting it at 0.9 times price to tangible book. The spreads on their loans, both international and domestic, seem to be growing. Certainly a lot of efficiencies in the banking sector. Sumitomo Mitsui also trades in New York Stock Exchange, trades over here in ADR form. and it's another one of the big banks in Japan that I think have become more profitable. Watch out for yen strengthening. I mean, we talk about the yen weakness. That has been fantastic for Japan. And the ultimate beneficiary of yen weakness is Toyota. So Toyota Motors would be the third name, and it's had a massive run.

20:49It's up 28 % year to date. We've had a lot of really interesting conversations on this desk about the evolution of hybrid EV and where that may be where the story is in the competitive landscape in the U.S. You're back to pre-COVID levels on SARS. Toyota as well positioned as anybody here in the U.S. and globally. That's Japan. When you look at Japan, I agree on Toyota if you want to talk granular stocks. But when you look at it, I like it going through the EWJ. But if you go back 34 years or so, that's how long it's taken to take out that top. So we don't know. Is this a double top? Could it pretend a fall from here?

21:24If you look at inflation rates, they're falling pretty precipitously. And that's been a catalyst. That's been a tailwind. So I'm not sure if they've proven themselves, but I like Toyota. Toyota, I mean, if you look, the prior all-time high, I think, was 200-ish around January of 2022. We blew through that. Maybe you get a back and fill to that level. But the EWJ, I think the all-time high was 73. We're at the near shot of that. So granularly, Toyota, absolutely. You're looking for pullbacks to buy this stock. But none of these stocks are actually in your acronym for the year. Is that correct? What is the acronym?

21:56Well, so the I in bicept is IDVO, which is the ticker of this international ETF that grows payout levels like a lot of these Japanese companies. I'll just say this. For Japan, who took four decades. We did. Look at that. Look how happy I look there. I mean, bicept. Nice job. I mean, look, at the family dinner table, people sometimes can be friendly, too. And I don't deserve the bicept. But I'll say this about Japan. And we've waited four decades for them to go to fresh all-time highs. I think the chartists would say this is the kind of a breakout that's actually interesting, and it's probably got some ways to go, in my view.

Read the full transcript

22:33All right. There's a lot more fast money to come. Here's what's coming up next. Just a few weeks left in winter, but crypto seems to be thawing out early. The big moves in Bitcoin and the proxy players seeing a boost. Next. Plus, more gains out of the weight loss drug trade, but this time it's a different Danish pharma stock surging. How this company is trying to tip the scales. Ahead, you're watching Fast Money live from the Nasdaq market site in Times Square. We're back right after this.

23:08Welcome back to Fast Money. Bitcoin on a tear this month up almost 28 percent, closing back in on the$55 ,000 level today. Rival crypto Ethereum doing even better, soaring nearly 40 percent in February. And crypto proxies like Coinbase, MicroStrategy and the Grayscale Bitcoin ETF are all coming along for the ride. How much higher can this crypto trade go? Tim, I think you're thinking hopefully higher with Coinbase. I think it can go higher. And again, Coinbase is my proxy. Everybody's got different proxies. I think people have overthought the dynamic around the Bitcoin ETF and the fallout, because if anything, all it does is signify there's a greater addressable market.

23:45There's greater follow through. It's interesting because yields are kind of moving higher. If anything, you know, we've got some Fed speak this week. We have a PCE on Thursday. Inflation sticky. and less Fed, less dynamics have been great for Bitcoin. But I just think the institutional adoption has made it kind of an all clear. There's obviously plenty of deliberation about where in the cycle you want to be. Oh, good, Dan. I'd love to hear what you said. Quickly, I was going to say, you've mentioned their balance sheet. Steve talked about this. Robinhood's breaking out of like, what is Louisiana, what she used to say, the longer the base, the higher the highest.

24:20Everybody at once. So they keep getting more revenue from the crypto. And their balance sheet's very good. and we've had this basing formation for the last two and a half years. Now it's trading north of 15 bucks. I mean, this is a stock that looks like it wants to go higher from here. Yeah, I'll just say this. So the proxies, you guys just mentioned two different ones. I think his is probably better at this stage than yours because everyone knows that one. Pointing, too. No, no. But I think what's become really clear is that if you want exposure to Bitcoin, then buy Bitcoin. Buy an ETF in your IRA.

24:50Buy SpotBit. You know what I mean? That sort of thing. Well, now that's an option. Yeah, but my point is, but why have all the idiosyncratic risk of a company that has competition, that has to maintain margins, that has to do all this stuff? Just buy the Bitcoin. Yes. I'll tell you why. But you own it as well. It's not as if you don't. I own Bitcoin. I own Ethereum. But I own Coinbase. And I've owned it for the last six months. And my view is that the on-ramp to digital assets has been Coinbase. And so unlike buying a micro strategy where I think you really have a Bitcoin, you know, since you have it on your balance sheet, that's kind of what you're buying.

25:24I think in Coinbase you have you have the margin, you have the opportunities and other products and other assets. I realize it's not simple, but I think that's the point. I actually think that there's a greater profitability that's not priced into this stock. And I think you get the higher beta on it. So I'm long marathon digital and I'm also long. I've been on the proxies on the on the proxies. Correct. It was up 21 percent, 22 percent. Marathon Digital today. I bet it was up 6 percent. So I own them both. We joke around. I joke around, call it a Texas hedge. Right. So you own you own the futures and you own the cattle.

25:56But you get that outsized performance based on that. So Ethereum is the one you buy going into the ETF approval process, which should be happening in the summer. All right. Coming up, the weight loss drug battle is expanding a Danish pharma stock that isn't Novo Nordisk. the surging on positive drug results, what it means for competition in the space, and whether the new player can be a heavy hitter. And some after hours action to bring you shares a Zoom and workday on the move after reporting results. The details out of those quarters when Fast Money returns back in two. Missed a moment of fast?

26:29Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

26:40Welcome back to Fast Money Stocks. Kicking off the week in the red, the S &P retreating from its record high notch last Friday, down nearly four-tenths of a percent. The Dow dropping 62 points and the Nasdaq down about a tenth of a percent. Shares of Domino's Pizza, though, jumping nearly six percent after its results this morning. The restaurant chain saying it will raise its dividend by 25 percent starting March 9th and increase its buyback program by an additional$1 billion. And some stocks hitting records today, Hilton, TJX, Costco, AbbVie, Waste Management, just some of the names at all-time highs.

27:10And Amazon also trading near its highest level in more than two years after its first trading day on the Dow Jones Industrial Average. The stock replacing Walgreens Boots Alliance on that index. Let's also check in shares of Expedia, the company announcing it will cut 1 ,500 jobs, almost 9 % of its workforce. It will take a charge of between$80 and$100 million related to those layoffs. A new experimental obesity drug from Danish company Zeeland Pharma is stoking investor hopes about the wider health benefits of weight loss treatments. The company's latest data showing significant improvement of fatty liver disease in patients studied in a phase two trial, sending Copenhagen listed shares of Zeeland soaring 35 percent.

27:49More on what this means for competition in the obesity space. We are joined by Jared Holes, health care sector strategist at Mizuho. Jared, it's always great to see you. what's interesting about this is that they squarely address mash which is this fatty liver disease and not obesity and yet there's this jump that this will be an obesity drug right um it's debatable whether that's going to come to fruition or not i think when you got two major players already the study not designed for obesity designed designed for fatty liver disease and a bunch of other metabolic diseases that kind of like underlie that condition.

28:25We just don't know. I mean, it's interesting. Alt Immune is working on a similar construct for obesity specifically. I think we just have to wait a little bit more until we kind of figure out what this mass market actually is, because as of right now, it seems like it's a subset of obesity. Right. And if Lillian Novo can kind of address the more mild to moderate population, We just don't know how big these other drugs are going to be. The study is sort of, it's not, I don't want to say it's not a clean study, but there are some differences. It looked like it studied people with less severe MASH in terms of its stages, whereas Lilly was looking at more severe cases.

29:06It also, as you pointed out, you know, studied a certain molecule that they have plus terzapatide. So we don't really know what the efficacy is. Is it possible that the notion is that it addresses the mash market, which takes away one potential driver for the obesity drugs, or is that just not? Yeah, I mean, I think that's how a lot of the street is looking at it. There are different pockets within this mash market. I mean, there are complexities to it we don't have to get into now, but they're mild to moderate. They're severe. it seems like Zeeland and other competitors that are going after this specific indication are kind of looking at the more severe patient populations because I think Lilly and Novo would probably tell you the same thing they think that the that the glyps are going to work for the mild to moderate the F1 and F2 patients in this particular category F3 and F4 potentially Zeeland altimmune madrigal which is going to supposedly get their drug approved next month or it's on the docket to get approved.

30:05So maybe the moderate, mild to moderate, Lillinovo, more severe, which is a smaller subset of the population, goes to, you know, these smaller biotech companies. But sort of just, you know, taking a bigger view of this whole space, I mean, does this just sort of, you know, a week ago we never heard of, or the general population, you may have heard of Zeeland Pharma. Right. But we never discussed Zeeland Pharma ever on this desk. It never came up in conversation. All of a sudden we're talking We have Zeeland Pharma listed in Denmark. Right. Does this just sort of underscores the notion? Fifty bucks, Guy, if you can name the currency in Denmark.

30:38Fifty bucks. I'll take it out of my pocket right now. Kroner. Oh, come on, man. Well, you just came back from COVID. He didn't know that. He came back from COVID. All right. Fantastic. Anyway. You still owe me 50. Does this sort of underscore the notion that there are competitors or potential, you know, companies out there developing potential drugs that we just have never even heard about? Yeah, for sure. For the institutional investor that is not just trading health care stocks or just biotech stocks, there are so many of these. I mean, we've discussed structure on here before, Altimmune, Viking.

31:09The list goes on. Corbis, Terns. There are many of these small players that are all kind of angling either towards obesity, towards a pocket of this market like fatty liver disease. So we're going to keep on hearing about it. And it's so obvious that there are more of these players. Roche did a multibillion-dollar deal buying a private company late last year. There are going to be more of these that we and I'm sure, you know, I'm missing a lot of them. But doesn't this tell me then I should be selling Lily here? I mean, if you're telling me there's a competitive landscape where everybody is catching up and we're paying, you know, look, an extraordinary tech like multiple for Lily.

31:44Yeah. The one thing I would say, Tim, on this thing is when you consider the investment needed just to kind of manufacture and then commercialize these drugs, given the market size. We saw what Novo Nordisk did a couple of weeks ago with$11 billion purchase of just three manufacturing facilities. And Lilly has kind of earmarked, I think, at least$3 to$4 billion this calendar year for that. I just don't know how biotech companies in this construct of the market that we're talking about can afford to do that level of investing. So I think for the time being, Lilly and Novo way ahead. But what happens when, say, you know, Merck buys them?

32:21And then, you know, I mean. Big cap farmer. And then suddenly that big cap farmer is in a great position to throw all the bankroll they need at it. I think that would be, that's the trade. Right. That if you think that there's going to be a consolidation wave here, Merck is going to get into this market. AbbVie, we've already seen AstraZeneca do a deal. We saw Roche do a deal. There are going to be more competitors here. I just think Lilly and Novo still, at this stage of the game, a lot of these data sets that we're talking about here with small cap biotech are very early. I just think there's time.

32:49So, Lillia, it's three-quarters of a trillion dollar market cap sitting on top of$50 billion of revenues next year. What does that revenue number have to be to justify that type of market cap, in your opinion? It's got to be close to, pretty close to$100 billion in time. Okay, fair enough. So, can they double revenues in the next, because that's the math, right? I mean, doubling revenues over the next year and a half to justify the valuation. No, no, not in the next year and a half. But in the next three, four, five years, it's feasible. Still, I think that's, you know, a little bit liberal to assume.

33:23But I think in the next few years, they could. Certainly not next year. But they have all the cards. They have the best drug in the category. Zepbound just launched at the end of last year. We're kind of in, like, the, you know, top of the first inning with that. So I think there's time. And, yes, I think it will grow into the multiple. It's been an incredibly awe-inspiring kind of like stock to just look at in the framework of health care. Just we don't we don't see these moves too often. Even Moderna only peaked to 250 billion at like, you know, during the craze of the pandemic. And here we are.

33:57This thing is 750. So, yeah. Jared, great to have you. Thank you. Thank you. For an in-depth look at how obesity drugs have reinvented weight loss culture. Be sure to tune in this Thursday, 10 p.m. Eastern for the premiere of my new documentary, Big Shot, the Ozembek Revolution, that's right here on CNBC. Right on. Coming up, a sleeper software stock and a fintech company poised for major growth at a big discount. Those are two of Julie Beal's top small cap picks and the names and why she thinks time is now to look for big opportunities in these smaller names. Plus, some after hours action in the cloud, Zoom and Workday on the move after the latest results.

34:30We'll have the numbers and the latest commentary from the calls next. And during February, we are celebrating Black Heritage, here's a CEO of M &T Bank.

34:41As a Black CEO of a Fortune 500 company, I may be an exception, but it's important to remember that there are many exceptional people who create positive change and inspire others every day. Black Heritage Month gives us that opportunity to celebrate the many exceptional, absolutely extraordinary people in our black and brown communities across America.

35:07Welcome back to Fast Money, a double earnings alert for you. Zoom video surging and extended trading up right now by just about 9%, 9.5 % after beating on the top and the bottom lines. Meantime, Workday moving in the opposite direction. That stock is down by more than 8 % despite an earnings beat on Q4 revenues that were in line with estimates. CNBC's Pippa Stevens has a detail on both of them. Let's start off with Zoom, Pippa. Hey, Melissa. So while it wasn't only a beat for Zoom, but also upbeat guidance with Q1 revenue and EPS estimates ahead of expectations, revenue from its enterprise customers, a key growth division, also ahead of street account estimates, with full-year enterprise revenue rising nearly 8 percent year over year.

35:45Now, Zoom also announced a$1.5 billion buyback and said it saw average monthly churn of 3 percent during the latest quarter, which was down slightly year over year. Now, shares of Workday taking a hit despite better than expected earnings numbers, with the company reiterating its full-year subscription revenue guidance. Vital knowledge is Adam Crisofuli noting the largely inline report could be an issue for investors who are hoping for more upside. The company also announced plans to acquire HiredScore, which is an AI-powered talent software company. Those shares down more than 8%. Melissa? Pippa, thank you.

36:20Pippa Stevens. Zoom, if you may recall, is what? Oh, the Z and Zebra. Z and Zebra. Yes, it is. Well, here's the deal about Zoom. So 34 % of their market cap is in cash, a very profitable company, 78 % gross margin. It's been left for dead. And that's one of the reasons why I was looking at it this year to kind of outperform a little bit here. So when they talk about a billion and a half buyback, I mean, that's just accretive. The stock trades at 13 and a half times. So to me, I actually think this company gets taken over by the end of this year. But right now, I mean, a beat and a raise is good enough.

36:50You're just talking about high multiple software type stocks. and here's Workday not living up to expectations. Well, it's been a roller coaster for high multiple software companies over the last couple of weeks. Obviously, you had Adobe, you had Palo Alto, you had a big, big comeback in a couple of those stocks too. But look, software today along with semis, same old story. All right, coming up, a small cap opening. One of our Fast Money traders says the time is now to get into the space. Julie Beal will make her case and run us through some of her big ideas. More Fast Money in two.

37:27Welcome back to Fast Money. Small caps might be the next place to look for opportunity. According to Fast Money trader Julie Beal, she says that no matter how you pick them, the group is attractive. She is here to share some of her picks. Hey, Julie, nice to see you. Hi. How are you guys? As a group, small caps are trading more attractively than mid and large? Yeah, I mean, they're inexpensive relative to mid and large, but they're also inexpensive relative to themselves historically. Historically, they're kind of trading at multi-decade lows. And to me, that actually makes a ton of sense, right?

37:58Small caps tend to be more cyclical, more sensitive. It's harder for them to raise capital in difficult times. And they are still in a bit of an earnings recession. But if you kind of look under the hood, you can find small cap names that are much higher quality and that are actually growing their earnings. And they're not that expensive. So I think it's kind of an opportunity, if you are willing to do the work, to find some really nice little undiscovered gems. One I would think of was a company called Blackline Technologies. This is kind of in the sleepy domain of accounting software. But what's wonderful is their founder has returned to the business.

38:32And I think that's always a great sign when you get the founder back in the business and they can focus on the things they really care about, which in this case is running the product and not talking to sloppy investors like me, yuck. And I think they're really starting to turn their profitability around. And there's still a lot of low hanging fruit for this business. So and compelling opportunity. The other one I like is Endava. This is a business that has been able to grow revenue over time. It's also founder-led with a strong ownership interest in the business. And what this gives you is the opportunity to participate in a lot of the FinTech and payments markets, but without having to choose who the winners are gonna be.

39:12Endava is an IT provider, and so they help you decide who you should be using to upgrade your technology suite, but they're agnostic as to who that is. And so they're in this really nice position where they leverage their reputation and they give you a compelling value proposition in terms of how to install and implement all that software. So I think these are two interesting businesses. Both of the founders run the business and they own a lot of stock themselves. So you're aligned with them. And that makes a big difference for long-term investors. Julie, in terms of the stocks, And Davos might be so bad that it's good.

39:45I say that because Morgan Stanley and HSBC both downgraded the stock last month. I think JP Morgan initiated neutral. But all the price targets have been raised to about 80 bucks or so, which is significantly higher than we are now. Is that it? The stock's just so depressed now that people are finding value? Yeah, I think there's pressure in terms of where they are in their cycle and the momentum in their business. They had a lot of momentum kind of coming out of COVID. And now people are a little bit concerned that while the long term looks really good, the near term it's going to be hard for them to kind of keep repeating that business.

40:17But I think if you can kind of look through the valley of that, it's still a real opportunity for investors. Do you need small caps as a group to trade better in order for these individual stocks to trade better, Julie? No, I mean, there are plenty of very expensive small cap names that are high quality. It helps. It certainly doesn't hurt when small cap becomes more in favor. But, you know, the quality rises to the top over the long term. There's going to be near term periods where small cap just is out of favor no matter what you do. But I think you should always have at least a small part of small cap in your balanced portfolio diet.

40:50All right, Julie, great to see you. Thank you. Thank you, Julie Beal. Anybody here in small caps right now? I tell you, small caps, I think, are the ultimate growth kind of conduit. conduit if you feel it's happening and if you feel and clearly they have underperformed. We've wrestled with when those turning points are coming underperformed year to date. So my Westrock is as close as I can get to a small cap name, my portfolio. But I like what Julie's doing. She's sifting through all the rest of them for profitable companies because 40 percent of the IWM is unprofitable. So they've lagged so far behind what she is going to make a lot of money on is when we start cutting rates, this whole group should outperform.

41:32She's crawling through the wreckage. Dave Edmonds. Dave Edmonds band. Yeah. Nice. Who was in Rock Pile with Nick Lowe. Sorry, Mel. That's what happened. Does anybody care? Dave Edmonds cares. Nick Lowe cares. Up next, Final Trades. That's how much I care.

42:02Time for the final trade. Let's go around the horn. Tim. Yeah, enjoyed that Japan conversation. So Tokyo Mitsubishi, MUFG, the JP Morgan of Japan trades cheap in my view. Steve. SoFi, great earnings report. Last go around. It gave some back. It's climbing and retracing. SoFi, technicals. Dan. Yeah, Rivian got trashed last week. I thought it would make a new all-time low. It did. It might fill in that gap back towards 15. Guy. I'm seeing it on Twitter. A rock pile, Mel. So you're in the minority on this one, I'm just saying. But welcome back, Steve, Mel, and Tim. Good to be here. Happy birthday, Karen.

42:36Chevron, CVX on the sell-off. All right, thank you for watching Fast Money. See you back here tomorrow at 5 for more Fast Mad Money with Jim Cramer starts right now.

42:47All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:21To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

Google grappling with some hard times as the stock lags its peers and its AI issues mount.

Can the tech titan turn things around? Or could a C-Suite shake up be on the table? Plus, move over Mounjaro…there could be new competition in the weight loss drug battle. The other Danish company making waves with their new results, and how they could tip the scales.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
The Struggle Is Real For Alphabet… And A New Player In The Weight Loss Drug Battle 2/26/24CNBC's "Fast Money" · 43 min
Listen in VO